PCSK9 and acute coronary syndrome: Since the clinical benefit of PCSK9 inhibitors seen in the FOURIER (Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk) and ODYSSEY (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) outcome trials occurred in a setting of reducing LDL-C to unprecedentedly low levels (e.g. < 15 mg/dL), it has become of interest to investigate offsetting adverse effects (Table 1) [44].